Archives: Agenda

Sponsored by EmVenio

Join us in the atrium for a drinks reception

• AI has accelerated site identification and feasibility through predictive analytics and historical data.
• ICON’s OneSearch platform enables faster identification of high-performing sites.
• AI alone cannot resolve all study start-up challenges.
• Successful site selection requires human-centered strategies beyond capacity metrics.
• Resource constraints and operational complexity make site success increasingly challenging.
• This session explores how ICON’s approach has evolved over five years of AI-driven selection, combining technology with human-centred strategies.

Artificial intelligence (AI) is transforming R&D procurement from a transactional function into a strategic, data-driven discipline across all industries. As the backbone of clinical business operations, vendor management processes are equally impacted, including onboarding, qualification, risk tracking, and governance. This session will explore how AI-enabled solutions are set to redefine traditional Excel-based workflows, promising efficiency, scalability, and strategic decision-making.

This session will explore:

• How AI transforms R&D procurement from transactional to strategic.
• New trends: Excel-based workflows are being replaced by intelligent automation.
• Vendor onboarding, risk, and governance become data-driven and scalable.
• Procurement shifts from cost control to value creation.

• Addressing logistical challenges in clinical trials for blood sample processing
• Implementing solutions to stabilize biomarkers at collection and simplify workflows

• Reframing clinical readiness in oncology: Why trial success is increasingly determined upstream—through mechanistic validation, patient stratification, and translational alignment before first-in-human dosing.
• Clinical Trials in a Dish platform: How patient-derived iPSC and organoid disease models can be deployed to predict responder populations, evaluate combination strategies, and inform biomarker-guided trial design.
• Leveraging academic ecosystems: Integrating biobanks, molecular datasets, and investigator networks to accelerate translational insight and enable more targeted, recruitment-efficient oncology trials.
• Capital-efficient development strategies: Using functional precision modeling to reduce late-stage attrition, optimize cohort sizing, and deploy clinical budgets with greater signal-to-cost discipline.

• Aligning in-house capacity to outsourcing needs to ensure your biotech sticks to budget
• Understanding when it is time to outsource to ensure sufficient oversight and management of all vendors
• Looking ahead to identify your biotech needs to integrate services seamlessly into current processes

• A 50-year retrospective on the escalating costs, stagnant timelines, and the attrition crisis in general and oncology drug development
• An analysis of the “Biomarker Revolution” and its profound historical influence on phase transition success rates, clinical trial durations, and evolving reimbursement models
• How integrating predictive biomarkers into clinical design eliminates the “noise” of non-responders and can multiply the overall probability of drug approval by a factor of five
• The Omios Biologics Solution: How we are utilizing a proprietary computational platform to develop the first biomarker-guided, systemic oncolytic viruses

In a world of increasing volatility—supply chain disruption, climate pressure, and shifting consumer expectations—protecting food is protecting people. This presentation will explore how dairy industry leaders can strengthen performance across the value chain by focusing on:

• Using end-to-end automation and digital tools to lift yield, uptime, and quality
• Packaging innovations that extend shelf life and improve sustainability
• Scaling new dairy and hybrid products efficiently from pilot to full production